Gold nanoprobes methodology for diagnosis of Multi-Drug Resistant Tuberculosis

Pedrosa P.¹, Veigas B.^{1,2}, Diana Machado^{3,4}, João Perdigão⁵, Isabel Portugal⁵, Isabel Couto^{3,6}, Miguel Viveiros^{3,7}, Baptista P.V.^{1*}

¹ CIGMH, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia,

Universidade Nova de Lisboa, Caparica, Portugal ² CENIMAT/I3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal.

³ Grupo de Micobactérias, Unidade Microbiologia Médica, Universidade Nova de Lisboa (IHMT/UNL), Portugal

⁴ Unidade de Parasitologia e Microbiologia Médicas, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa (IHMT/UNL), Portugal

⁵ Centro de Patogénese Molecular/URIA, Faculdade de Farmácia, Universidade de Lisboa, Lisboa,

Portugal

⁶ CREM, Centro de Recursos Microbiológicos, Universidade Nova de Lisboa, Portugal ⁷ COST ACTION BM0701 (ATENS), Portugal

*pmvb@fct.unl.pt

Abstract

Tuberculosis (TB), still one of the leading human infectious diseases, reported 8.7 million new cases in 2011 alone. Also, the increasing rate of multidrug-resistant tuberculosis (MDRTB) and its treatment difficulties pose a serious public health problem especially in developing countries [1]. Resistance to isoniazid and rifampicin, first line antibiotics, is commonly associated with point mutations in *inhA*, *katG*, and *rpoB* genes of *Mycobacterium tuberculosis* (Mtb), the main etiologic agent of human TB [2]. Therefore, the development of cheap, fast and simple molecular methods to access susceptibility profiles would have a huge impact in the capacity of early diagnosis and treatment of MDRTB patients.

Gold nanoparticles functionalized with thiol-modified oligonucleotides (Au-nanoprobes) have shown the potential to provide a rapid and sensitive detection method for Mtb and of single base mutations associated with antibiotic resistance [3], namely the characterization of the 3 most relevant codons in *rpoB* gene associated to rifampicin resistance [4].

Here we extend the Au-nanoprobe approach towards discriminating specific mutations within *inhA* and *katG* genes in PCR amplified DNA from clinical samples. Using a multiplex PCR reaction for *inhA* and *rpoB* genes, it is possible to assess both *loci* in parallel, and might extend the Au-nanoprobe method's potential to MDRTB molecular characterization at a point-of-need. We have also optimized the detection procedure using loop mediated isothermal amplification (LAMP) so as to avoid standard PCR, and applied it to discriminate between *rpoB531WT* and *rpoBS531L* mutations.

References

[1] World Health Organization Document 2012 WHO/HTM/TB/2012.6

- [2] Parsons L.M., Somoskövi A., Gutierrez C., Lee E., Paramasivan C.N., Abimiku A., Spector S., Roscigno G., Nkengasong, 2011 J. Clin. Microbiol. Rev. 24 (2) 314-50
- [3] Doria G., Baumgartner B., Francob R., Baptista P.V., 2010 Colloids and Surfaces B: Biointerfaces 77 (1) 122–124
- [4] Veigas B., Machado D., Perdigão J., Portugal I., Couto I., Viveiros M., Baptista P.V., 2010 Nanotechnology 21 (41) 415101



Figure 1: After a first round of Multiplex PCR with *inhA* and *rpoB* sets of primers the Au-nanoprobe assay is performed for mutation detection. Aggregation is measured by ratio of non-aggregated particles (SPR intensity at 526nm) versus aggregated particles (SPR intensity at 600nm) with the two sets of probes (*inhA* and *rpoB*). Two Au-nanoprobes within the same set are used to create redundancy in the system. The graphs shown in the figure are illustrative and do not contain real data.



TO WHOM IT MAY CONCERN

Caparica, 23rd of November 2012

I hereby declare that Mr Pedro Pedrosa has been developing his MSc research project under my supervision at Nanotheranostics Group at Centre for Research in Human Molecular Genetics. The submitted abstract is part of the results attained thus far and, as Thesis Adviser, I fully support the submission for communication.

If you require any further information, please do not hesitate and contact me.

Sincerely,

Pedro Viana Baptista, PhD Assistant Professor with Tenure Nanotheranostics Group Centre for Research in Human Molecular Research Dept. of Life Sciences Faculdade de Ciências e Tecnologia Universidade Nova de Lisboa

Campus da Caparica 2829-516 CAPARICA	Tel.: +351 21 294 8530 Fax: +351 21 294 8530 sec-dtv @fct.unl.pt	www.fct.unl.pt
	$(1,1,\infty,N,\gamma,\alpha,\alpha,\beta,\beta,\beta,\beta,\beta,\beta,\beta,\beta,\beta,\beta,\beta,\beta,\beta,\beta,\beta,\beta,\beta$	